The trial randomized patients with high-risk PC to treatment with androgen-deprivation therapy (ADT; degarelix 240 mg subcutaneously) given two weeks prior to RP (Cohort A) or to cyclophosphamide (200 mg/m2 intravenously) and a Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting allogeneic cellular vaccine (GVAX; composed of 2.5 × 108 PC3 cells and 1.6 × 108 LNCaP cells, injected intradermally) plus ADT given two weeks prior to RP (Cohort B). The gene discussed is CSF2; the disease is pachyonychia congenita.